-transparent.png){kind=logo}
In 18 patients with generalised myasthenia treated with oral pyridostigmine, muscular strength, decrement of neuromuscular transmission in the trapezius muscle on repetitive accessory nerve stimulation, and pyridostigmine plasma level were measured repeatedly during 1-3 dosing intervals. Significant correlations between pyridostigmine concentrations and functional parameters were present in three out of 11 cases in which plasma levels changed by at least 25 ng/ml during the investigational period and peak levels did not exceed 100 ng/ml. Several other observations indicated that pyridostigmine at levels above 100 ng/ml may impair neuromuscular function.
Related Publications
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
May 1987,
Neurology,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
February 1981,
Neurology,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
February 1977,
Clinical pharmacology and therapeutics,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
November 1977,
Neurology,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
October 1987,
Archives of neurology,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
August 1955,
Revista clinica espanola,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
October 2011,
Clinical drug investigation,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
February 1992,
Ugeskrift for laeger,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
June 1985,
Fortschritte der Neurologie-Psychiatrie,
U Breyer-Pfaff, and
A Schmezer, and
U Maier, and
A Brinkmann, and
F Schumm
December 1981,
Journal of neurology, neurosurgery, and psychiatry,
